Cargando…
Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation
Oral anticoagulants (OACs) have been used to prevent stroke/systemic embolism (SE) among patients with non-valvular atrial fibrillation (NVAF). To evaluate baseline clinical characteristics, incidence rates of stroke/SE and hospitalization for bleeding, and OAC use among elderly patients with NVAF i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550860/ https://www.ncbi.nlm.nih.gov/pubmed/37530954 http://dx.doi.org/10.1007/s11239-023-02855-1 |
_version_ | 1785115641843286016 |
---|---|
author | Atwater, Brett D. Di Fusco, Manuela Keshishian, Allison Delinger, Rachel Ferri, Mauricio Jiang, Jenny Seigel, Lauren Yuce, Huseyin Guo, Jennifer D. |
author_facet | Atwater, Brett D. Di Fusco, Manuela Keshishian, Allison Delinger, Rachel Ferri, Mauricio Jiang, Jenny Seigel, Lauren Yuce, Huseyin Guo, Jennifer D. |
author_sort | Atwater, Brett D. |
collection | PubMed |
description | Oral anticoagulants (OACs) have been used to prevent stroke/systemic embolism (SE) among patients with non-valvular atrial fibrillation (NVAF). To evaluate baseline clinical characteristics, incidence rates of stroke/SE and hospitalization for bleeding, and OAC use among elderly patients with NVAF in the US by geographic region. Patients with NVAF were selected from the US Centers for Medicare & Medicaid Services claims database (01JAN2013-31DEC2016). Twelve months of health plan enrollment was required before and after the NVAF diagnosis to evaluate baseline characteristics and outcomes, respectively. Each patient was assigned to a 3-digit zip code based on their primary residence, and geographic variation was visualized using ArcGIS Pro software. Over 2.8 million patients with NVAF were identified. Large geographic variation was observed in clinical characteristics, stroke/SE, hospitalization for bleeding, and OAC use among patients across the US. The zip codes with the highest mean CHA(2)DS(2)–VASc scores and frequency of prior bleeding also had the highest incidence of stroke/SE and hospitalization for bleeding. Across 3-digit zip codes, 35–63% of patients were untreated. Overall, the incidence of stroke/SE and hospitalization for bleeding were higher and OAC treatment was less frequent in zip codes located in the Southern US. Baseline clinical characteristics, incidence rates of stroke/SE and hospitalization for bleeding, and OAC usage vary considerably by 3-digit zip code in the US. The additional granularity provided in this study may help clinicians to identify small regions with high-risk of stroke/SE and hospitalization for bleeding and low use of OAC that may benefit from targeted care strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11239-023-02855-1. |
format | Online Article Text |
id | pubmed-10550860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-105508602023-10-06 Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation Atwater, Brett D. Di Fusco, Manuela Keshishian, Allison Delinger, Rachel Ferri, Mauricio Jiang, Jenny Seigel, Lauren Yuce, Huseyin Guo, Jennifer D. J Thromb Thrombolysis Article Oral anticoagulants (OACs) have been used to prevent stroke/systemic embolism (SE) among patients with non-valvular atrial fibrillation (NVAF). To evaluate baseline clinical characteristics, incidence rates of stroke/SE and hospitalization for bleeding, and OAC use among elderly patients with NVAF in the US by geographic region. Patients with NVAF were selected from the US Centers for Medicare & Medicaid Services claims database (01JAN2013-31DEC2016). Twelve months of health plan enrollment was required before and after the NVAF diagnosis to evaluate baseline characteristics and outcomes, respectively. Each patient was assigned to a 3-digit zip code based on their primary residence, and geographic variation was visualized using ArcGIS Pro software. Over 2.8 million patients with NVAF were identified. Large geographic variation was observed in clinical characteristics, stroke/SE, hospitalization for bleeding, and OAC use among patients across the US. The zip codes with the highest mean CHA(2)DS(2)–VASc scores and frequency of prior bleeding also had the highest incidence of stroke/SE and hospitalization for bleeding. Across 3-digit zip codes, 35–63% of patients were untreated. Overall, the incidence of stroke/SE and hospitalization for bleeding were higher and OAC treatment was less frequent in zip codes located in the Southern US. Baseline clinical characteristics, incidence rates of stroke/SE and hospitalization for bleeding, and OAC usage vary considerably by 3-digit zip code in the US. The additional granularity provided in this study may help clinicians to identify small regions with high-risk of stroke/SE and hospitalization for bleeding and low use of OAC that may benefit from targeted care strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11239-023-02855-1. Springer US 2023-08-02 2023 /pmc/articles/PMC10550860/ /pubmed/37530954 http://dx.doi.org/10.1007/s11239-023-02855-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Atwater, Brett D. Di Fusco, Manuela Keshishian, Allison Delinger, Rachel Ferri, Mauricio Jiang, Jenny Seigel, Lauren Yuce, Huseyin Guo, Jennifer D. Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation |
title | Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation |
title_full | Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation |
title_fullStr | Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation |
title_full_unstemmed | Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation |
title_short | Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation |
title_sort | geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550860/ https://www.ncbi.nlm.nih.gov/pubmed/37530954 http://dx.doi.org/10.1007/s11239-023-02855-1 |
work_keys_str_mv | AT atwaterbrettd geographicvariationinclinicaloutcomesandanticoagulationamongmedicarebeneficiarieswithnonvalvularatrialfibrillation AT difuscomanuela geographicvariationinclinicaloutcomesandanticoagulationamongmedicarebeneficiarieswithnonvalvularatrialfibrillation AT keshishianallison geographicvariationinclinicaloutcomesandanticoagulationamongmedicarebeneficiarieswithnonvalvularatrialfibrillation AT delingerrachel geographicvariationinclinicaloutcomesandanticoagulationamongmedicarebeneficiarieswithnonvalvularatrialfibrillation AT ferrimauricio geographicvariationinclinicaloutcomesandanticoagulationamongmedicarebeneficiarieswithnonvalvularatrialfibrillation AT jiangjenny geographicvariationinclinicaloutcomesandanticoagulationamongmedicarebeneficiarieswithnonvalvularatrialfibrillation AT seigellauren geographicvariationinclinicaloutcomesandanticoagulationamongmedicarebeneficiarieswithnonvalvularatrialfibrillation AT yucehuseyin geographicvariationinclinicaloutcomesandanticoagulationamongmedicarebeneficiarieswithnonvalvularatrialfibrillation AT guojenniferd geographicvariationinclinicaloutcomesandanticoagulationamongmedicarebeneficiarieswithnonvalvularatrialfibrillation |